Compare Roundhill Magnificent Seven ETF (MAGS) vs Recursion Pharmaceuticals Inc (RXRX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Roundhill Magnificent Seven ETF vs Recursion Pharmaceuticals Inc — how do they compare? Roundhill Magnificent Seven ETF trades at $73.45 (market cap $5.78B), while Recursion Pharmaceuticals Inc trades at $3.99 (market cap $2.14B). The key difference: Roundhill Magnificent Seven ETF is far larger — about 2.7× Recursion Pharmaceuticals Inc's market cap, and Roundhill Magnificent Seven ETF is trading nearer its 52-week high, Recursion Pharmaceuticals Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Roundhill Magnificent Seven ETF for 36 Days and Recursion Pharmaceuticals Inc for 22 Days on average.
| MAGS | RXRX | |
|---|---|---|
Market Cap | $5.78B | $2.14B |
Volume | 4,410,665 | 30,789,535 |
Sector | Sector/Thematic | Health |
52-Week High | $73.90 | $6.79 |
52-Week Low | $55.39 | $2.84 |
Typical Hold Time | 36 Days | 22 Days |
Enterprise Value | — | $1.66B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MAGS (Roundhill Magnificent Seven ETF) trades at $73.69, down 0.28% with a bullish technical signal from moving averages. The ETF provides equal-weighted exposure to seven mega-cap tech leaders, though it has underperformed the S&P 500 in 2026 with only 2% YTD gains. Recent news highlights AI-driven momentum from holdings like Meta and NVIDIA, but also notes the Magnificent Seven theme showing signs of fracturing as capital spending pressures dividends and buybacks.
The outlook remains cautiously optimistic given AI supercycle potential, but concentration risk and valuation concerns persist. Key opportunities include pure-play exposure to AI growth engines, while risks involve market rotation away from mega-caps and aggressive capital expenditure cycles impacting shareholder returns. Technical support sits at $73 with resistance at $74-75.
RXRX trades at $4.27, down 7.78% today, with technical indicators showing a bullish trend despite recent weakness. The company reported Q2 2026 earnings miss after two consecutive beats, with revenue declining to $54 million in 2026 from $74 million in 2025. While maintaining a negative net income margin of -961.97%, RXRX continues to expand its AI-powered drug discovery platform through strategic partnerships with Tempus and Roche.
The stock presents high-risk growth potential with strong analyst support (40% buy rating) but faces significant execution challenges. Investment appeal hinges on successful pipeline development and commercialization of AI drug discovery technology, though persistent losses and declining revenue create substantial downside risk for shareholders.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Roundhill Magnificent Seven ETF
MAGS is an ETF that provides concentrated exposure to the seven technology-focused mega-cap companies often referred to as the 'Magnificent Seven' (Alphabet, Amazon, Apple, Meta, Microsoft, NVIDIA, and Tesla). The fund is designed to capture the performance of these market-leading stocks, which have been the primary drivers of market returns. It offers a simple way for investors to invest solely in this select group of high-growth technology companies.
Read more on MAGS →About Recursion Pharmaceuticals Inc
Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company leveraging artificial intelligence (AI) and machine learning to industrialize drug discovery. The company's unique approach combines one of the world's largest biological and chemical datasets with automated wet-lab and computational systems to map human biology and identify potential therapeutic candidates across a range of diseases, including oncology and rare diseases. Recursion aims to accelerate the traditionally slow and expensive process of drug development.
Read more on RXRX →
